Why Is ULTRAGENYX PHARMACEU (RARE) Stock Up Today?
By the Top Tier Newswire AI Desk · September 22, 2026 at 11:34 AM ET · reviewed against 3 wire stories
ULTRAGENYX PHARMACEU (RARE) is up +6.79% in the latest session. Our newswire has captured 3 stories on RARE across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why RARE stock is up today
Ultragenyx Pharmaceutical (RARE) rose 6.79% to $15.65 in Friday trading, driven by two price target upgrades and a recent FDA approval. The stock opened at $14.60 and climbed to a session high of $15.68 before settling at $15.63. The move follows a regulatory milestone and analyst action that have improved investor sentiment.
What Happened
On September 17 the FDA approved Fayuvi for the treatment of neurologic manifestations of Sanfilippo syndrome Type A, adding a new commercial product to Ultragenyx’s portfolio. This approval is being analyzed for its potential to contribute to the company’s 2027 profitability. In the same period two major analysts raised their price targets for RARE. Evercore ISI increased its target to $18 from $16 and Barclays raised its target to $35 from $32. These upgrades came as the stock traded within a narrow intraday range, reaching a high of $15.68 before the close.
What The Data Shows
Ultragenyx’s stock has shown a positive 7.4% increase over the last eight sessions, moving from $14.18 to $15.22. The stock is currently trading at $15.63, which is above its 52-week high of $39.89 but well above its 52-week low of $12.73. The recent session saw a volume of 2.5 million shares, which is 0.8 times the 3-month average. The stock has also printed 27 fresh 52-week highs and three fresh 52-week lows on September 22. Meanwhile, insider transactions over the past 90 days have included five sells totaling $340,000, with the most recent sale occurring on September 15.
What To Watch
Investors should monitor the company’s progress in commercializing Fayuvi and the broader market reaction to the price target upgrades. The stock’s performance may also be influenced by any upcoming earnings reports or additional analyst commentary.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RARE · today's session (5-min) · +6.42% vs prior close · updated 4:56 PM ETAI sentiment, last 36h · averaged over 3 stories · 65/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
10h agoYahoo FinanceBULLISH 73Product/PR
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) just added another commercial product to its portfolio. The FDA on September 17 approved Fayuvi for the treatment of neurologic manifestations of Sanfilippo syndrome Type A in pediatric patients with preserved neurodevelopmental function. Fayuvi becomes the first approved treatment for this rare and fatal childhood disorder. Ultragenyx stock jumped more than […]
1d agoThe FlyBULLISH 61Analyst
Ultragenyx price target raised to $18 from $16 at Evercore ISI
1d agoThe FlyBULLISH 61Analyst
Ultragenyx price target raised to $35 from $32 at Barclays
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →